Trials / Completed
CompletedNCT00005967
Tipifarnib in Treating Patients With Advanced Hematologic Cancer
A Dose Finding Study of R115777 (NSC 702818) in Patients With Advanced Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- National Cancer Institute (NCI) · NIH
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
Detailed description
OBJECTIVES: I. Determine the relationship between tipifarnib dose and inhibition of farnesylation in malignant cells of patients with advanced hematologic malignancies. II. Determine the safety profile of this drug in this patient population. III. Determine the clinical activity of this drug in these patients. OUTLINE: This is a randomized study. Patients are randomized to 1 of 4 dose levels. Patients receive oral tipifarnib twice daily for 21 days. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After 1 course of therapy, patients may receive subsequent therapy at the maximum tolerated dose at the investigator's discretion.
Conditions
- Chronic Myeloproliferative Disorders
- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Myelodysplastic Syndromes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tipifarnib |
Timeline
- Start date
- 2000-08-01
- Primary completion
- 2004-04-01
- First posted
- 2003-01-27
- Last updated
- 2013-02-11
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00005967. Inclusion in this directory is not an endorsement.